VEEV › analyze
VEEV · Analyze
Date: June 4, 2026 | Price at Analysis: ~$167.24 (June 3 close post-earnings) Sector: Healthcare — Health Information Services (Life Sciences Vertical SaaS) Market Cap: ~$27.3B | 52-Week Range: $148.05 – $310.50 Prior Analysis: April 28, 2026 (stale — full refresh with Q1 FY2027 data)
BREAKING: Q1 FY2027 Earnings (Reported June 3, 2026 After Close)
| Metric | Guidance | Actual | Beat |
|---|---|---|---|
| Total Revenue | $855–858M | $882.9M | +$25M (+3%) |
| Subscription Revenue | — | $730.2M (+15% YoY) | — |
| Non-GAAP EPS | $2.13–2.14 | $2.24 | +$0.10 (+4.7%) |
| Non-GAAP Op. Income | — | $395M (45% margin) | — |
FY2027 Guidance Update: Revenue $3.585–3.600B (prior $3.570–3.585B, raised ~$15M). Non-GAAP operating income ~$1.610B (~44% margin). The commercial subscription raise includes ~$10M from the Ostro acquisition.
Phase 1 — Fundamentals Analyst
Income Statement Summary (FY = ends Jan 31)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total Revenue | $2,155M | $2,364M | $2,747M | $3,195M |
| Gross Profit | $1,546M | $1,686M | $2,047M | $2,413M |
| Gross Margin | 71.7% | 71.3% | 74.5% | 75.5% |
| Operating Income (GAAP) | $459M | $429M | $691M | $916M |
| Op. Margin (GAAP) | 21.3% | 18.2% | 25.2% | 28.7% |
| Net Income | $488M | $526M | $714M | $909M |
| Diluted EPS | $3.00 | $3.22 | $4.32 | $5.44 |
| R&D | $520M | $629M | $693M | $767M |
| SG&A | $566M | $628M | $662M | $730M |
| Interest Income | $46M | $134M | $208M | $267M |
Revenue CAGR (FY2023–FY2026, 3yr): 14.0% Net Income CAGR (FY2023–FY2026, 3yr): 23.1% EPS CAGR (FY2023–FY2026, 3yr): 22.0%
Note: FY2024 GAAP operating margin dip to 18.2% was a transition year artifact during Vault CRM build-out — non-GAAP margins were consistent throughout.
Cash Flow Statement
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Operating Cash Flow | $780M | $911M | $1,090M | $1,415M |
| Free Cash Flow | $780M | $911M | $1,090M | $1,415M |
| Capex (implied) | ~$0M | ~$0M | ~$0M | ~$0M |
| Stock-Based Compensation | $352M | $394M | $437M | $473M |
| Buybacks | $0 | $0 | $0 | $170M |
Note: Yahoo reports FCF = Operating Cash Flow for Veeva (minimal capex — pure SaaS). True capex is embedded in "Net Other Investing Changes" (~$29M in FY2026 for software capitalization).
FCF CAGR (FY2023–FY2026, 3yr): 21.9% FCF/Share (reported): $7.72 SBC as % of Revenue: 14.8% (FY2026) — significant but stable SBC-Adjusted FCF: $1,415M – $473M = $942M → $5.75/share adjusted
Balance Sheet Highlights
| Metric | FY2026 | Notes |
|---|---|---|
| Total Assets | $8,979M | |
| Cash + ST Investments | $6,561M | ~$40/share |
| Total Debt | $96M | All capital lease obligations — zero financial debt |
| Debt-to-Assets | 1.1% | Fortress balance sheet |
| Common Equity | $7,215M | |
| Book Value Per Share | $44.05 | |
| Tangible Book Value | $6,745M | |
| TBVPS | $41.18 | |
| Deferred Revenue (current) | $1,489M | Strong forward revenue visibility |
| Goodwill | $440M | Stable — no acquisition sprees |
Net Cash Position: $6,561M – $96M = $6,465M (~$39.45/share) — 24% of current market cap in cash
Shares Outstanding Trend
| Year | Basic Shares | Change |
|---|---|---|
| FY2023 | 158.2M | baseline |
| FY2024 | 161.3M | +2.0% |
| FY2025 | 162.6M | +0.8% |
| FY2026 | 163.8M | +0.7% |
Dilution is modest (+1.2%/yr over 3 years) and decelerating. FY2026 marks first buyback activity ($170M). Not alarming but SBC at 14.8% of revenue remains a structural drag on per-share economics.
Capital Allocation (FY2026)
| Use | Amount | % of FCF |
|---|---|---|
| R&D Investment | $767M | 54% of FCF |
| SG&A / Growth | $730M | 52% of FCF |
| Buybacks | $170M | 12% of FCF |
| M&A | $0 | 0% |
| Dividends | $0 | 0% |
| Net Cash Accumulation | ~$1.3B added to balance sheet | — |
Capital allocation is R&D-first, consistent with a platform company building out Vault CRM and Falcon AI. The $1.3B annual cash accumulation on the balance sheet is becoming a notable optionality item — management has signaled no large M&A appetite, suggesting eventual buyback acceleration or special dividends.
Per-Share Metrics Summary
| Metric | Value |
|---|---|
| Revenue/Share | $19.51 |
| FCF/Share (reported) | $7.72 |
| FCF/Share (SBC-adjusted) | $5.75 |
| EPS (diluted, GAAP) | $5.44 |
| Net Cash/Share | $39.45 |
| TBVPS | $41.18 |
Fundamentals Verdict: Exceptional balance sheet. FCF CAGR of 22% with zero debt and $6.5B cash is genuinely unusual. The primary flag is SBC — at $473M/yr, it consumes 33% of reported FCF and 14.8% of revenue. Real economic FCF is $5.75/share, not $7.72. Still, on an SBC-adjusted basis, the business is generating and compounding cash at an elite rate.
Phase 1 — Sentiment & Intelligence Analyst
Q1 FY2027 Earnings Reaction (June 3, 2026)
Veeva delivered a clean beat across every metric. Revenue of $882.9M vs. $855–858M guidance (+3%) and EPS of $2.24 vs. $2.13–2.14 guidance (+4.7%) shows the business is fundamentally outperforming expectations. The guidance raise of ~$15M for FY2027, while modest, signals management confidence.
CEO Peter Gassner's key framing: "Transitioning from an industry-specific application company to an industry-specific application and AI agent company." This is the biggest strategic signal in several quarters — Gassner is formally declaring the AI agent layer (Falcon) as a new revenue pillar, not just a product feature.
Falcon AI Agent Specifics: - Targets high-volume, repetitive tasks: clinical document processing, safety case triage - Pricing model: likely per-document or per-case (consumption-based, not seat-based) - Early deployment stage — not yet material to revenue but building customer proof points - Strategy is "agent replaces the job, not just assists" — ambitious positioning
Vault CRM Migration Status: - 9 of top 20 pharma committed to Vault CRM (Veeva's next-gen CRM replacing Salesforce-built prior platform) - Salesforce Life Sciences Cloud has won 3-4 of top 20 (including one top-3 pharma per Salesforce claims) - Migration is ongoing — this is the key competitive battleground for FY2027–FY2028
Competitive Intelligence: Salesforce Threat
The Salesforce Life Sciences Cloud threat has escalated but is not a thesis-breaker:
- Salesforce claims: 40+ life sciences customers signed including Takeda, Pfizer, Boehringer Ingelheim, Fresenius Kabi — including one top-3 global pharma
- Veeva's position: 9 of top 20 pharma committed to Vault CRM vs. Salesforce's 3 — Veeva's Vault (regulatory, clinical, quality) has no credible competitor and is not threatened
- The CRM battleground is specific to commercial/salesforce automation — Salesforce's threat is in commercial CRM, not in Vault (regulatory, clinical, quality). ~70% of Veeva's revenue is Vault-based
- Key dynamic: Large pharma companies splitting — some dual-vendor, some going all-in on Veeva, a few going Salesforce. The "traffic jam" risk (decision delays during migration) is real but creates a timing headache, not an existential threat
Analyst Reactions Post-Q1
- Consensus PT: $262.68 (22 of 30 analysts Buy/Strong Buy)
- Recent PT changes: Morgan Stanley raised to $205 (Feb 2026); Citi downgraded and cut PT from $291 → $176 (April 10, 2026)
- Post-Q1 PT (from search): At least one firm raised to $314.71 citing Q1 beat and guidance raise
- Current consensus PT (updated): $275.69 (per MarketBeat as of June 2026)
Insider Activity
Net insider selling of ~$4M over last 12 months — modest. COO Priscilla Hung filed intent to sell ~2K shares (~$314K at ~$157). Not alarming — routine executive liquidity at normal levels. No large cluster selling.
Institutional Trends
Mixed: 519 institutions added in the most recent quarter while 689 decreased positions — net reduction during Q1 2026 market volatility. Not a red flag; likely tax-loss selling and portfolio rebalancing during the February-May selloff that took VEEV from $240 to $148.
Ostro Acquisition
Small tuck-in acquisition (~$10M contribution to commercial subscription guidance for FY2027). Ostro provides AI-powered patient engagement for the biopharma commercial segment. Bolt-on, not transformational.
S&P 500 Inclusion (May 2026)
VEEV joined the S&P 500 in May 2026 — a structural demand catalyst that brought forced buying from index funds. The ~$30 price spike in May ($235 → $280 range) was partially S&P inclusion-driven. The current pullback to $167 post-inclusion pop reflects normalization plus broader market volatility.
Sentiment Verdict: Bullish. Q1 was a clean beat. Gassner's AI agent framing is credible and opens a new growth vector. The Salesforce threat is real and tracked, but Vault is uncontested and CRM battle is manageable. Analyst community is overwhelmingly positive post-Q1 with consensus PT ~$275 (65% upside from current).
Phase 1/2 — Moat Analyst
Qualitative Assessment
The Core Moat: Regulated Vertical Lock-In
Veeva's competitive moat is one of the most defensible in enterprise software. The life sciences industry — pharma, biotech, CROs, medical device manufacturers — operates under some of the most stringent regulatory frameworks in the world (FDA 21 CFR Part 11, EMA, ICH guidelines). Veeva has embedded compliance, audit trails, and validated workflows directly into its products. This is not a feature — it is the entire value proposition.
Switching costs are extreme. When a pharmaceutical company uses Vault to manage a drug's regulatory submissions, clinical data, quality documents, and safety cases, the switching cost is not measured in dollars but in validation cycles, regulatory risk, and potential FDA compliance gaps. A pharmaceutical company that switches EDC systems mid-trial risks data integrity findings. No CFO approves that switch for competitive reasons alone.
Revenue Stream Analysis:
| Product | Revenue Share | Competitive Status |
|---|---|---|
| Vault (Regulatory, Clinical, Quality, Safety) | ~70% of revenue | Near-monopoly. No credible alternative. |
| Commercial CRM (Vault CRM + legacy) | ~25% of revenue | Contested — Salesforce attacking |
| Commercial Data (Crossix, Iqvia overlap) | ~5% of revenue | Competitive; niche differentiation |
Critical insight: The competitive battle with Salesforce is in the ~25% commercial CRM bucket, not the ~70% Vault bucket. Even a worst-case Salesforce outcome (winning 40% of CRM share) would impact only ~10% of Veeva's total revenue. Vault is the moat.
Adversarial Stress Test: How Would a Rival Kill This?
-
Salesforce route: Build a validated, life sciences-specific CRM and attack commercial. Status: Actively happening. Salesforce has traction with 3-4 top-20 pharma. But Vault is unchallenged. Verdict: Manageable — threatens growth rate, not core business.
-
AWS/Google/Microsoft route: Build a cloud-native, FDA-validated data platform. Status: Not happening. Cloud hyperscalers lack domain expertise and are more likely to partner (AWS partnership with Veeva exists) than compete. Regulatory validation expertise takes 5-10 years to build. Verdict: Low probability in 5-year horizon.
-
AI disruption route: LLM-native competitors build AI-first regulatory/clinical platforms that bypass Veeva's legacy architecture. Status: Early-stage risk. A startup like a "Veeva killer" using Claude/GPT-4 for regulatory document automation could theoretically undercut per-seat pricing. But: (a) FDA validation requirements create massive moat even for AI tools, (b) Veeva is building Falcon to occupy this space first, (c) pharma companies are deeply risk-averse about replacing validated software. Verdict: 5-10 year watch item, not a near-term threat.
-
Customer concentration erosion: Top 20 pharma decide to build in-house platforms. Status: This happened with IQVIA as a partial alternative in some areas. But: economies of scale favor a vertical SaaS vendor. Verdic: Tail risk, not a credible mass defection scenario.
Moat Verdict: Wide and durable. The Vault platform has no credible competitor. Commercial CRM is the contested flank — worth monitoring quarterly (top-20 pharma commitment count is the key metric). AI agents (Falcon) represent Veeva either extending its moat or the biggest risk to its own pricing model.
Quantitative Moat Metrics
| Metric | FY2023 | FY2024 | FY2025 | FY2026 | Trend |
|---|---|---|---|---|---|
| Gross Margin | 71.7% | 71.3% | 74.5% | 75.5% | ↑ Improving |
| GAAP Op. Margin | 21.3% | 18.2% | 25.2% | 28.7% | ↑ Expanding |
| ROIC (GAAP) | ~12% | ~10% | ~13% | ~13.4% | → Stable-ish |
| Net Income Margin | 22.6% | 22.2% | 26.0% | 28.4% | ↑ Improving |
| Deferred Revenue Growth | baseline | +21% | +22% | +17% | ↑ Strong |
ROIC on a GAAP basis (~13-14%) appears moderate, but this is significantly understated because (a) the $6.5B cash pile earns interest but is counted in the denominator without corresponding operating income credit, and (b) SBC inflates APIC and equity base. Ex-cash ROIC is meaningfully higher.
Gross margin expansion from 71.3% to 75.5% over 3 years reflects operating leverage as Vault platform matures — a genuine moat signal. Every dollar of new subscription revenue flows through at ~80%+ incremental margins.
Evergreen Rating: 8/10. Vault's regulatory/clinical/quality applications are tied to regulated drug development — a process that will not change regardless of AI, macro, or competitive dynamics. Commercial CRM is the variable. Falcon AI is optionality. The core business is as evergreen as enterprise SaaS gets.
Phase 2 — Valuation Analyst
No dividend — DDM and DYT not applicable. Applying Graham, Bogle, and FCF-based models.
Graham's Intrinsic Value
Graham's Number = √(22.5 × EPS × BVPS) = √(22.5 × $5.44 × $44.05) = √(5,394) = $73.44
Graham's Number is drastically below current price, as expected for a high-quality, low-leverage, high-growth SaaS company with minimal tangible assets. Graham's formula is designed for asset-heavy industrials and banks — it is structurally inapplicable to asset-light software compounders. Using it as a hard floor would be a category error. Filed as reference only; weighted 0% in final fair value.
Bogle's Expected Return Model
Formula: Dividend Yield + EPS Growth Rate ± P/E Change
- Dividend yield: 0%
- EPS growth rate (forward consensus/implied): ~15-18% (FY2027 guided non-GAAP operating income growth ~25%; GAAP EPS harder to project due to tax rate normalization, but mid-teens earnings growth is conservative)
- Current trailing P/E: 29.7x | Forward P/E: 16.7x
- P/E trajectory: The forward P/E of 16.7x vs trailing 29.7x reflects significant near-term earnings step-up from FY2026 to FY2027. At stable P/E: Expected return = 0% + 15% = ~15%/year
- If P/E compresses from 29.7x → 25x over 3 years: ~(-3% annual headwind) → ~12%/year
- If P/E expands back toward 35x (pre-selloff levels) over 3 years: ~(+5% annual tailwind) → ~20%/year
Bogle range: 12–20% expected annual return at current price. Favorable.
FCF-Based Fair Value (Primary Model)
Veeva is best valued on FCF — specifically enterprise value vs. SBC-adjusted FCF, then add net cash.
Base Case (25x SBC-adj FCF): - SBC-adj FCF: $942M (FY2026) growing at 15% → FY2027E = ~$1,083M - EV at 25x: $27.1B - Add net cash: +$6.5B → Total equity value = $33.6B - Shares: 163.8M → $205/share
Bull Case (30x SBC-adj FCF + 18% FCF growth): - FY2027E SBC-adj FCF: ~$1,112M - EV at 30x: $33.4B - Add net cash: +$6.5B → $39.9B / 163.8M = $244/share
Bear Case (20x SBC-adj FCF + 10% FCF growth, Salesforce wins 5 more top-20 accounts): - FY2027E SBC-adj FCF: ~$1,036M - EV at 20x: $20.7B - Add net cash: +$6.5B → $27.2B / 163.8M = $166/share
EV/FCF Check (reported FCF): - Current EV: $27.3B mktcap - $6.5B cash + $0.1B debt = ~$20.9B - FY2026 FCF: $1,415M → EV/FCF = 14.8x — remarkably cheap on reported FCF for this quality - Even SBC-adjusted: $20.9B / $942M = 22.2x EV/SBC-adj FCF
Q1 FY2027 Forward Projection
Using Q1 FY2027 actual ($882.9M) × 4 annualized = $3,532M — but management guided $3,585–3,600B for full year, implying Q1 was the seasonally strongest quarter and H2 accelerates modestly. Non-GAAP operating income ~$1,610M at 44% margin.
FY2027 implied non-GAAP EPS: ~$8.50-9.00 (rough estimate; tax and SBC normalization apply) Forward non-GAAP P/E at $167: ~$167 / $8.75 = 19.1x — reasonable for this quality
Fair Value Range Summary
| Model | Fair Value | Weight |
|---|---|---|
| Graham's Number | $73 | 0% (inapplicable) |
| FCF Base Case (25x, FY2027E) | $205 | 45% |
| FCF Bull Case (30x) | $244 | 20% |
| FCF Bear Case (20x) | $166 | 15% |
| Bogle Implied (15% return over 3yr) | ~$230 (3yr price target) | 20% |
Weighted Fair Value: ~$205–215
At $167, VEEV is trading below the base fair value estimate of $205 and roughly at the bear-case floor of $166. The stock has de-rated significantly from its 52-week high of $310.50 (-46%) and is now pricing in significant Salesforce competitive risk that the fundamentals — particularly the Q1 beat — don't yet justify.
Prior analysis fair value was $195–215. Updated range: $200–220, reflecting Q1 earnings upgrade.
Phase 3 — Tension & Debate Round
Key Tension: Q1 Beat vs. Above Buy Zone
The setup: The prior watchlist entry defined the buy zone as $148–168. VEEV is currently at $167.24 — technically within the zone on the lower end after the post-earnings pullback from $179 (the price at analysis request time). However, the question remains: has the fundamental picture improved enough to justify buying here vs. waiting?
Fundamentals/Valuation position: YES, buy here. - EV/SBC-adj FCF of 22.2x is the cheapest the stock has been since 2022 lows - Q1 FY2027 beat by $25M confirms the growth trajectory is intact - FY2027 guidance of $3.585-3.600B represents 12.3% revenue growth with margin expansion to 44% - The stock is pricing in Salesforce winning a war it hasn't won — Vault (70% of revenue) is unthreatened - Net cash of $39.45/share means you're buying the operating business at ~$128/share (stripping out cash), which is 17x SBC-adj FCF — exceptional for this quality
Moat/Sentiment position: CAUTIOUS, but not opposed. - Salesforce traction (40+ customers including one top-3 pharma) is a real data point, not FUD - The CRM migration is not complete — Vault CRM is mid-deployment for top-20 pharma. Execution risk is real through FY2028 - Falcon AI is unproven as a revenue driver — it's a future option, not current value - Institutional net selling in Q1 and insider selling suggest smart money is not aggressively accumulating at these levels - The stock was at $310 six months ago, fell to $148, and is now at $167 — the volatility profile suggests patience may be rewarded
Debate resolution: The valuation case wins decisively at $167. The EV/FCF and forward earnings picture supports buying here. The moat concerns are legitimate but relate to commercial CRM (25% of revenue), not Vault (70%). The bear case floor is essentially the current price. The asymmetry is favorable: downside ~0-5% to the bear case, upside ~25-35% to base fair value.
However: The prior buy zone ($148–168) was established correctly. The stock touched $148 in April 2026. If you had not yet initiated, the staged entry protocol still applies: - Stage 1 (50% of position): $160–168 — you are here - Stage 2 (50% of position): $148–155 — on any further pullback - Do not chase above $175 for a new position
Phase 4 — Manager's Weighted Verdict
Summary Assessment
Veeva Systems is a rare business: a near-monopoly in a regulated vertical with zero financial debt, $6.5B in net cash, 22% FCF CAGR, and expanding gross margins. The Q1 FY2027 earnings beat — revenue $882.9M vs. $855-858M guidance — confirms the growth trajectory is intact despite Salesforce competitive noise.
What the market is pricing in at $167: 1. Salesforce wins meaningful commercial CRM share (partially true — 3-4 top-20 pharma is not nothing) 2. Growth decelerates significantly (not supported by Q1 data or FY2027 guidance of $3.585-3.600B) 3. AI disruption threatens the core Vault platform (not credible — regulated validation workflows are uniquely resistant)
What the market is ignoring: 1. Vault (70% of revenue) has zero credible competitor 2. EV/SBC-adj FCF of 22x is the cheapest entry point since 2022 3. $39.45/share in net cash (~24% of market cap) creates a hard floor 4. Falcon AI opens a consumption-based revenue layer that doesn't exist in current models 5. S&P 500 inclusion creates structural demand from passive flows
Risk Factors
- Salesforce CRM erosion (PRIMARY): If Salesforce wins 8–10 of top-20 pharma commercial CRM, that's ~8–10% of total revenue at risk. Growth could slow to single digits. Monitor quarterly commitment count.
- Vault CRM migration execution (ELEVATED): Mid-deployment transitions create customer friction and potential delayed renewals. Watch net retention rate.
- AI disruption (MEDIUM, 3-5yr): LLM-native competitors could undercut pricing in document automation. Veeva's Falcon strategy is the correct response, but execution is unproven.
- Valuation re-rating (LOW at current price): At 22x EV/SBC-adj FCF, there's limited further de-rating risk unless Salesforce wins dominate and growth goes to <8%.
- SBC dilution (ONGOING): $473M/yr SBC is a structural drag. Real FCF yield is ~3.4% vs. reported 4.6%.
Conviction Score Update
Previous conviction: [7.5]
Q1 FY2027 beat + favorable valuation at $167 + Vault moat intact + Falcon AI optionality = net positive update.
Updated conviction: [8.0]
The improvement is driven by: (1) Q1 beat confirming growth trajectory, (2) valuation now at base fair value floor (22x EV/SBC-adj FCF), (3) Gassner's Falcon AI framing opening a credible new revenue vector. The Salesforce threat prevents a higher score — this is not a [9] until the commercial CRM battle is resolved in Veeva's favor.
Portfolio Strategist Context
VEEV is unowned. The portfolio has strong healthcare underexposure (only NVO, which is distressed). Adding VEEV would: - Add healthcare exposure via a high-quality, cash-generative compounder - Reduce portfolio correlation risk (VEEV is largely uncorrelated to most existing holdings) - Not add income (no dividend), but contributes to the growth pillar - Represent a unique vertical SaaS exposure the rest of the portfolio lacks
Recommended position size: 2–3% of portfolio (consistent with other quality watchlist initiations like MANH, SHOP). Larger than MANH given the higher conviction and more established moat.
Entry Strategy
| Tranche | Price Zone | Allocation | Rationale |
|---|---|---|---|
| Stage 1 | $155–168 | 50% of target position | Current territory; EV/FCF favorable |
| Stage 2 | $145–155 | 35% of target position | Near 52wk low; adds conviction |
| Stage 3 | $135–145 | 15% of target position | Deep value if Salesforce fears spike |
| Average target entry | ~$155 | ||
| Trim | $250+ | Near base fair value | |
| Strong sell | $280+ | Above bull case FV |
Thesis break conditions: - Vault CRM top-20 pharma commitment count falls below 7 (current: 9) - Revenue growth decelerates to <10% for 2 consecutive quarters - Salesforce wins 6+ additional top-20 pharma accounts (cumulative 10+) - FY2028 guidance implies margin compression
Next monitoring event: FY2027 Q2 earnings (August/September 2026) — watch Vault CRM commitment count update, Falcon AI customer metrics, and whether FY2027 guidance holds.
Final Scorecard
| Dimension | Rating | Commentary |
|---|---|---|
| Financial Health | ★★★★★ | Zero debt, $6.5B cash, 22% FCF CAGR |
| Moat | ★★★★½ | Vault near-monopoly; CRM contested |
| Valuation | ★★★★ | Attractive at 22x EV/SBC-adj FCF |
| Sentiment | ★★★★ | Q1 beat; analyst community bullish |
| Growth Trajectory | ★★★★ | 14% rev CAGR; guided $3.6B FY2027 |
| Management Quality | ★★★★★ | Gassner founder-CEO; long-term orientation |
| Overall Conviction | [8.0] | Strong buy at $155–168 |
Fair Value Range: $200–220 (updated from $195–215) Current Price: ~$167 → ~20–25% discount to fair value Recommended Action: Initiate position — Stage 1 (50%) at current levels ($155–168)
Sources: - Veeva Q1 FY2027 Earnings Results — GuruFocus - Veeva Q1 FY2027 Earnings Call Transcript — Motley Fool - Peter Gassner Q1 FY2027 Prepared Remarks — Veeva IR - Veeva Systems Revenue FY2027 — StockTitan - Salesforce Life Sciences Cloud competitive analysis — IntuitionLabs - VEEV Analyst Price Targets — MarketBeat - VEEV Insider Activity — Simply Wall St - VEEV S&P 500 inclusion — Motley Fool